retatrutide peptide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— retatrutide clinical trials efficacy (RETA)

82 For patients with obesity and HFpEF, GLP-1 RAs, such as semaglutide, are safe, with fewer serious cardiovascular events reported

It is characterized by abdominal obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels

The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain bariatric surgery [78]

The so-called GLP-1 patches also release their active ingredients through the skin into the bloodstream by this mechanism

Cost, Insurance Coverage, and Access Public insurance coverage for GLP-1 obesity treatments is spotty in the United States